AG
VRTX icon

Aperio Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Aperio Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$41.5M Sell
175,611
-11,264
-6% -$2.58M 0.12% 161
2020
Q3 		$50.9M Sell
186,875
-7,162
-4% -$1.98M 0.17% 108
2020
Q2 		$56.3M Buy
194,037
+19,489
+11% +$5.28M 0.21% 90
2020
Q1 		$41.5M Buy
174,548
+30,852
+21% +$7.08M 0.18% 109
2019
Q4 		$31.5M Buy
143,696
+5,705
+4% +$1.15M 0.11% 197
2019
Q3 		$23.4M Buy
137,991
+10,103
+8% +$1.79M 0.09% 246
2019
Q2 		$23.5M Sell
127,888
-16,633
-12% -$2.91M 0.1% 243
2019
Q1 		$26.6M Buy
144,521
+16,805
+13% +$3.1M 0.11% 198
2018
Q4 		$21.2M Buy
127,716
+8,918
+8% +$1.55M 0.11% 221
2018
Q3 		$22.9M Buy
118,798
+8,018
+7% +$1.43M 0.1% 226
2018
Q2 		$18.8M Buy
110,780
+2,203
+2% +$341K 0.09% 256
2018
Q1 		$17.7M Buy
108,577
+8,246
+8% +$1.35M 0.09% 267
2017
Q4 		$15M Buy
100,331
+6,546
+7% +$969K 0.08% 303
2017
Q3 		$14.3M Buy
93,785
+9,294
+11% +$1.4M 0.08% 297
2017
Q2 		$10.9M Buy
84,491
+15,777
+23% +$1.9M 0.07% 354
2017
Q1 		$7.51M Sell
68,714
-1,119
-2% -$98.5K 0.05% 420
2016
Q4 		$5.14M Sell
69,833
-25,865
-27% -$2.1M 0.04% 493
2016
Q3 		$8.35M Buy
95,698
+14,934
+18% +$1.41M 0.06% 367
2016
Q2 		$6.95M Buy
80,764
+12,255
+18% +$1.06M 0.05% 403
2016
Q1 		$5.45M Sell
68,509
-2,303
-3% -$208K 0.05% 447
2015
Q4 		$8.91M Buy
70,812
+2,651
+4% +$320K 0.08% 282
2015
Q3 		$7.1M Buy
68,161
+8,207
+14% +$1.05M 0.07% 324
2015
Q2 		$7.4M Buy
59,954
+7,576
+14% +$955K 0.08% 306
2015
Q1 		$6.18M Buy
52,378
+4,629
+10% +$555K 0.07% 347
2014
Q4 		$5.67M Buy
47,749
+6,908
+17% +$778K 0.07% 348
2014
Q3 		$4.59M Buy
40,841
+9,137
+29% +$870K 0.06% 374
2014
Q2 		$3M Buy
31,704
+6,294
+25% +$441K 0.04% 483
2014
Q1 		$1.8M Buy
+25,410
New +$2.01M 0.03% 737
2013
Q4 		– Sell
-20,370
Closed -$1.42M – 771
2013
Q3 		$1.54M Buy
20,370
+4,380
+27% +$349K 0.03% 678
2013
Q2 		$1.28M Buy
+15,990
New +$1.18M 0.03% 662

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Aperio Group's VRTX Position: Q4 2020 in Review

Aperio Group reduced its Vertex Pharmaceuticals (VRTX) stake by 6% in Q4 2020, selling an estimated $2.58M and leaving 175,611 shares worth $41.5M. The position accounts for 0.12% of the portfolio, ranked #161.

Aperio Group first reported a position in VRTX in Q2 2013 and has held it in 30 quarters since. The position peaked at $56.3M in Q2 2020. 971 funds tracked by Wall St. Rank hold VRTX as of Q4 2020.

  • Aperio Group held 175,611 shares of Vertex Pharmaceuticals worth $41.5M as of Q4 2020.
  • Aperio Group sold 11,264 Vertex Pharmaceuticals shares in Q4 2020, an estimated $2.58M.
  • Vertex Pharmaceuticals made up 0.12% of Aperio Group's portfolio in Q4 2020, its #161 holding.
  • Aperio Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 30 quarters since.
  • Aperio Group's Vertex Pharmaceuticals position peaked at $56.3M in Q2 2020.
  • 971 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.